Lichen Planus Market to Surge Owing to Novel Biologics

The Global Lichen Planus Market focuses on therapies designed to manage and alleviate the symptoms of lichen planus, a chronic inflammatory dermatologic condition. Products in this market include topical corticosteroids, calcineurin inhibitors, systemic immunosuppressants, and emerging biologics that target specific immune pathways.

Lichen Planus Market  Topical steroids remain a cornerstone for mild to moderate cases due to rapid anti-inflammatory effects and ease of application, while systemic agents such as methotrexate and cyclosporine offer advantages for refractory or widespread disease by suppressing overactive immune responses. Novel biologic treatments, designed to inhibit cytokines and T-cell activation, promise improved efficacy and reduced side effects compared to conventional therapies. The market is driven by increasing diagnosis rates, patient demand for long-term remission solutions, and heightened awareness among dermatologists and primary care physicians. Further, research into targeted drug delivery systems enhances treatment adherence and patient quality of life. As pharmaceutical companies expand their pipelines with advanced formulations and personalized medicine approaches, the therapeutic landscape evolves rapidly.

The Global Lichen Planus Market is estimated to be valued at USD 161.8 million in 2025 and is expected to reach USD 273.7 million by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.

Get more insights on: Lichen Planus Market

Get this Report in Japanese Language: 扁平苔癬市場

Get this Report in Korean Language: 이끼플라누스시장

Get more related Articles on: Understanding Muckle Wells Syndrome